Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Quoted Artificial Intelligence Commercial

QUOTED. Nov. 5, 2018. Iya Khalil.

  • Interviews

Executive Summary

GNS Healthcare and its REFS (Reverse Engineering, Forward Simulation) AI platform is at the forefront of bringing targeted artificial intelligence solutions to biopharmaceutical companies, health plans and research organizations by helping to support better decision-making, better outcomes and cost savings. See what GNS cofounder Iya Khalil said about it here.

"Our goal is to not just predict disease. Our goal is to understand why you're getting a disease, so we know how to change it and to make recommendations as to what the best treatment is, or what the best biological new pathway to go after is." –Iya Khalil, cofounder, GNS Healthcare

Click here for a free trial of Medtech Insight

 
Table

View full table

Related Content

Medtech Insight

Topics

Tags:
Quoted Artificial Intelligence Commercial
Latest Headlines

Rise In Class I Device Recalls A ‘Grave Concern,’ Says FDA’s Anne Reid

Discreet Gait Freezing Solution Brings Therapy With The Tap Of An Apple Watch

Shuren Says CDRH Is ‘Turning The Ship Around’ As Operations Return To Normal

EU: Good News For IVDs And For Future Transparency Of Medtech Compliance

See All
UsernamePublicRestriction

Register

MT123502

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By